Abstract
Serum P-III-NP reflects fibriliogenesis. To study whether P-III-NP can be used to monitor growth, it was determined by two different radioimmunoassays. One recognizes predominantly the intact triple-stranded propeptide showing a lesser affinity to the smaller monomeric peptide (RIAgnost), while the other detects both forms equally (FAB). In healthy children (n=375, aged 0 to 16 years) p-III-NP determined with either assay followed closely growth velocity. Patients with Turner's-Syndrome (n=11: 17±4/90± 22 (RIAgnost/FAB in ng/ml respectively)), constitutional short stature (n=16: 19±5/105±27) and growth hormone deficiency (GHD) (n=23: 16±8/82±29) had low levels, while those with tall stature (n=11: 56±45/174±38) had high levels, which declined during estradiol-therapy in girls (n=3: 23±4/125±22). In GHD during recombinant growth hormone therapy (n=20) p-III-NP values increased after only 3 injections (p<0.01) and stayed elevated above baseline for 6 months (ms). Results were compared to growth (median 5.6 cm (0.4 to 13.9) in 6 ms) and to established methods of growth monitoring (somatomedin c, alkaline phosphatase). p-III-NP (FAB) values correlated with the individual growth rates during the first (r=0.40; p<0.05) and the second 3 ms (r=0.66; p<0.001) and the total 6 ms periods (r=0.46 p<0.05). All other parameters showed some association to growth only during one or two treatment periods. Thus, p-III-NP can be used for growth monitoring.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Danne, T., Grüters, A., Schnabel, K. et al. MONITORING GROWTH AND GROWTH HORMONE THERAPY BY SERUM DETERMINATION OF ANTIGENS RELATED TO THE AMINO-TERMINAL TYPE III PROCOLLAGEN PROPEPTIDE (P-III-NP). Pediatr Res 23, 123 (1988). https://doi.org/10.1203/00006450-198801000-00133
Issue Date:
DOI: https://doi.org/10.1203/00006450-198801000-00133